NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free EBS Stock Alerts $1.92 -0.03 (-1.54%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.90▼$2.0150-Day Range$1.53▼$3.4152-Week Range$1.42▼$10.88Volume880,900 shsAverage Volume2.61 million shsMarket Capitalization$100.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Emergent BioSolutions alerts: Email Address Emergent BioSolutions MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside160.4% Upside$5.00 Price TargetShort InterestBearish11.76% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($13.98) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.88 out of 5 starsMedical Sector204th out of 916 stocksPharmaceutical Preparations Industry77th out of 416 stocks 3.0 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.76% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently increased by 3.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 1.8 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Emergent BioSolutions this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($13.98) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Emergent BioSolutions Stock (NYSE:EBS)Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More EBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Stock News HeadlinesApril 24, 2024 | msn.comFDA approves Amneal's generic version of OTC NarcanApril 24, 2024 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Stock Price Passes Above 200-Day Moving Average of $2.25April 29, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 22, 2024 | globenewswire.comEmergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024April 17, 2024 | finance.yahoo.comInstitutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year lossesApril 1, 2024 | finance.yahoo.comAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveMarch 28, 2024 | globenewswire.comEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid CrisisMarch 27, 2024 | bizjournals.comWhy this Maryland biotech furloughed 130 workers in MichiganApril 29, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 25, 2024 | globenewswire.comEmergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing FacilityMarch 12, 2024 | marketwatch.comEmergent BioSolutions Shares Drop on S&P DowngradeMarch 7, 2024 | realmoney.thestreet.comBenchmark gets more bullish on Emergent BioSolutions, upgrades sharesMarch 7, 2024 | realmoney.thestreet.comEmergent BioSolutions upgraded to Buy at Benchmark after 'upbeat' Q4 reportMarch 7, 2024 | finance.yahoo.comEmergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comEmergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comQ4 2023 Emergent BioSolutions Inc Earnings CallMarch 7, 2024 | fool.comEmergent BioSolutions (EBS) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | investorplace.comEBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023March 6, 2024 | benzinga.comEmergent BioSolutions: Q4 Earnings InsightsMarch 6, 2024 | globenewswire.comEmergent BioSolutions Reports Fourth Quarter 2023 Financial ResultsMarch 6, 2024 | globenewswire.comEmergent BioSolutions Reports Fourth Quarter 2023 Financial ResultsMarch 6, 2024 | msn.comEmergent Biosolutions Q4 2023 Earnings PreviewMarch 4, 2024 | benzinga.comEmergent BioSolutions's Earnings: A PreviewFebruary 29, 2024 | globenewswire.comEmergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024February 27, 2024 | seekingalpha.comNew CEO Appointment A Clear Positive For Emergent BioSolutionsFebruary 21, 2024 | bizjournals.comBiotech with Baltimore facility taps new CEOFebruary 21, 2024 | investorplace.comWhy Is Emergent BioSolutions (EBS) Stock Up 70% Today?See More Headlines Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/28/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees1,600Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+160.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($14.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-72.11% Pretax Margin-69.68% Return on Equity-37.35% Return on Assets-14.81% Debt Debt-to-Equity Ratio0.69 Current Ratio1.04 Quick Ratio0.54 Sales & Book Value Annual Sales$1.02 billion Price / Sales0.10 Cash Flow$0.88 per share Price / Cash Flow2.18 Book Value$12.51 per share Price / Book0.15Miscellaneous Outstanding Shares52,391,000Free Float51,762,000Market Cap$100.59 million OptionableOptionable Beta1.20 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard S. Lindahl M.B.A. (Age 60)Executive VP, CFO & Treasurer Comp: $1.02MMs. Jennifer L. Fox (Age 51)Executive VP of External Affairs, General Counsel & Corporate Secretary Comp: $975.84kMs. Coleen Glessner (Age 53)Executive Vice President of Global Quality and Ethics & Compliance Comp: $959.37kMr. Paul A. Williams (Age 57)Senior Vice President of Products Business Comp: $846.97kMr. Joseph C. Papa Jr. (Age 68)CEO, President & Director Michelle PepinSenior VP & Chief Human Resource OfficerMs. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerDr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentWilliam HartzelSenior Vice President of Manufacturing & BioservicesMore ExecutivesKey CompetitorsRegulus TherapeuticsNASDAQ:RGLSBolt BiotherapeuticsNASDAQ:BOLTRigel PharmaceuticalsNASDAQ:RIGLFortress BiotechNASDAQ:FBIOMerrimack PharmaceuticalsNASDAQ:MACKView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 5,042 shares on 4/24/2024Ownership: 1.602%SeaCrest Wealth Management LLCBought 96,000 shares on 4/18/2024Ownership: 0.183%Los Angeles Capital Management LLCBought 32,460 shares on 4/5/2024Ownership: 0.372%Tower Research Capital LLC TRC Bought 6,823 shares on 2/13/2024Ownership: 0.038%Hilltop Holdings Inc.Sold 22,850 shares on 2/12/2024Ownership: 0.409%View All Insider TransactionsView All Institutional Transactions EBS Stock Analysis - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price target for 2024? 2 equities research analysts have issued 12 month target prices for Emergent BioSolutions' stock. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 160.4% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2024? Emergent BioSolutions' stock was trading at $2.40 at the beginning of the year. Since then, EBS shares have decreased by 20.0% and is now trading at $1.92. View the best growth stocks for 2024 here. Are investors shorting Emergent BioSolutions? Emergent BioSolutions saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Based on an average daily volume of 2,980,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 11.4% of the shares of the stock are sold short. View Emergent BioSolutions' Short Interest. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our EBS earnings forecast. How can I listen to Emergent BioSolutions' earnings call? Emergent BioSolutions will be holding an earnings conference call on Wednesday, May 1st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.44. The biopharmaceutical company had revenue of $276.60 million for the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 72.11%. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. What ETF holds Emergent BioSolutions' stock? Amplify Treatments, Testing and Advancements ETF holds 12,240 shares of EBS stock, representing 0.27% of its portfolio. What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions updated its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.60%), Los Angeles Capital Management LLC (0.37%) and SeaCrest Wealth Management LLC (0.18%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:EBS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.